R Dziadziuszko
Overview
Explore the profile of R Dziadziuszko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
873
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyer M, Peters S, Mok T, Lam S, Yang P, Aggarwal C, et al.
Ann Oncol
. 2024 Oct;
35(12):1088-1104.
PMID: 39413875
Background: Lung cancer remains a critical public health issue, presenting multifaceted challenges in prevention, diagnosis, and treatment. This article aims to review the current landscape of lung cancer research and...
2.
Besse B, Felip E, Garcia Campelo R, Cobo M, Mascaux C, Madroszyk A, et al.
Ann Oncol
. 2023 Sep;
34(10):920-933.
PMID: 37704166
Background: Patients with advanced non-small-cell lung cancer (NSCLC) treated with immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary resistance) or after durable benefit (secondary resistance). The cancer vaccine OSE2101...
3.
Remon J, Besse B, Aix S, Callejo A, Al-Rabi K, Bernabe R, et al.
Ann Oncol
. 2023 Mar;
34(5):468-476.
PMID: 36863484
Background: The APPLE trial aimed to evaluate the feasibility of longitudinal plasma epidermal growth factor receptor (EGFR) T790M monitoring for the best sequencing strategy of gefitinib and osimertinib. Methods: APPLE...
4.
Dziadziuszko R, Peters S, Ruf T, Cardona A, Guerini E, Kurtsikidze N, et al.
ESMO Open
. 2022 Nov;
7(6):100612.
PMID: 36375271
Alectinib is a preferred first-line therapy for patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) in several national clinical practice guidelines. The randomized, global, phase III ALEX...
5.
Morfouace M, Novello S, Stevovic A, Dooms C, Janzic U, Berghmans T, et al.
Sci Rep
. 2022 May;
12(1):8342.
PMID: 35585228
Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients...
6.
Blaszkowska M, Specht-Szwoch Z, Dziadziuszko R
ESMO Open
. 2022 Mar;
7(2):100449.
PMID: 35334419
No abstract available.
7.
Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn M, et al.
Ann Oncol
. 2022 Feb;
33(5):466-487.
PMID: 35176458
The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of...
8.
Wolf J, Helland A, Oh I, Migliorino M, Dziadziuszko R, Wrona A, et al.
ESMO Open
. 2022 Jan;
7(1):100333.
PMID: 35042152
Background: At the primary data cut-off, the ALUR study demonstrated significantly improved progression-free survival (PFS) and central nervous system (CNS) objective response rate (ORR) with alectinib versus chemotherapy in pretreated,...
9.
Putora P, Fischer G, Fruh M, Califano R, Faivre-Finn C, Van Houtte P, et al.
Radiother Oncol
. 2020 May;
149:84-88.
PMID: 32445987
Background: Brain metastases (BM) are common in patients with small cell lung cancer (SCLC). In recent years, the role of whole brain radiotherapy (WBRT) for brain metastases in lung cancer...
10.
Mok T, Camidge D, Gadgeel S, Rosell R, Dziadziuszko R, Kim D, et al.
Ann Oncol
. 2020 May;
31(8):1056-1064.
PMID: 32418886
Background: The ALEX study demonstrated significantly improved progression-free survival (PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell lung cancer (NSCLC) at the primary data cut-off (9 February 2017). We...